√是 □ 否 如否，请详细说明：_____________________________ 三、本人符合该公司章程规定的独立董事任职条件。 新里程健康科技集团股份有限公司 独立董事候选人声明 声明人池轶婷，作为新里程健康科技集团股份有限公司第六届董事会独 立董事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人 独立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳 证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明 如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √是 □否 如否，请详细说明：_____________________________ 二、本人符合中国证监会《上市公司独立董事规则》规定的独立董事任 职资格和条件。 √ 是 □ 否 如否，请详细说明：_____________________________ 四、本人已经参加培训并取得证券交易所认可的相关证书。 □ 是 √否 如否，请详细说明：本人承诺在本次提名后，参加深圳证券交易所举办 的最近一期独立董事资格培训并取得独立董事资格证书。 五、本人担任独立董事不 ...

证券简称：新里程 证券代码：002219 公告编号：2023-057 新里程健康科技集团股份有限公司 新里程健康科技集团股份有限公司 关于召开2023年第三次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2023 年第三次临时股东大会 （二）股东大会召集人：新里程健康科技集团股份有限公司（以下简称"公 司"）第六届董事会。 （三）会议召开的合法、合规性：本次股东大会的召开已经公司第六届董事 会第十二次会议审议通过，召集程序符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》等有关规定。 （四）会议召开的日期及时间： 1、现场会议时间：2023 年 8 月 28 日（星期一）下午 14:50 开始。 2、网络投票时间： 2023 年 8 月 28 日 2.1、通过深圳证券交易所交易系统进行网络投票的时间为：2023 年 8 月 28 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 2.2、通过深圳证券交易所互联网投票系统进行网络投票的时间为：2023 年 8 月 2 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2023-058 新里程健康科技集团股份有限公司 关于修订《公司章程》及《董事会议事规则》的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"公司"）于2023年8月11日召 开第六届董事会第十二次会议审议通过了《关于修订公司章程及董事会议事规则 的议案》，本议案尚须提交公司股东大会审议。现将具体内容公告如下： 为进一步提高公司董事会的决策能力和治理水平，更大程度地发挥董事的经 验和能力，拟将董事会成员人数调整为九至十三名。鉴于上述调整，根据《中华 人民共和国公司法》《上市公司治理准则》《上市公司章程指引》《深圳证券交易 所股票上市规则》等有关规定，拟对《新里程健康科技集团股份有限公司章程》 （以下简称"《公司章程》"）和《新里程健康科技集团股份有限公司董事会议事 规则》（以下简称"《董事会议事规则》"）中的相关条款进行同步修订。 一、《公司章程》具体修订内容对照如下： | 修订前 | 修订后 | | --- | --- | | 第一百 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2023-055 新里程健康科技集团股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 二、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 （一）审议通过《关于公司<2023 年半年度报告>及<2023 年半年度报告摘 要>的议案》 经审议，公司《2023年半年度报告》及《2023年半年度报告摘要》内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏，同意《关于公司<2023年半年度报告>及<2023年半年度报告摘要>的议 案》。 具体内容详见公司于2023年8月12日刊载在《证券时报》《证券日报》《中国 证券报》《上海证券报》和巨潮资讯网(http://www.cninfo.com.cn)的《2023年半年 度 报 告 摘 要 》（ 公 告 编 号 ： 2023-059 号 ） 及 同 日 刊 载 于 巨 潮 资 讯 网 (http://www.cninfo.com.cn)的 ...

第六届监事会第十次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2023-056 新里程健康科技集团股份有限公司 （一）审议通过《关于公司<2023 年半年度报告>及<2023 年半年度报告摘 要>的议案》 经审核，监事会认为董事会编制和审核的新里程健康科技集团股份有限公司 《2023年半年度报告》及《2023年半年度报告摘要》的程序符合法律、行政法规 和中国证监会的规定，报告内容真实、准确、完整地反映了公司实际情况，不存 在任何虚假记载、误导性陈述或重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届监事会第十次会议通知于2023年8月2日以书面、电子邮件、电话送达等方式发 出，会议于2023年8月11日以现场表决结合通讯方式表决在公司会议室召开。会 议由公司监事会主席李海涛先生召集并主持，公司现任监事3名，实际表决监事3 名，符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 。 经与会监事审议，会议审议通过了以下议案并做出 ...

证券代码：002219 证券简称：新里程 新里程健康科技集团股份有限公司 投资者关系活动记录表 编号：2023-03 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 业绩说明会 类别 □新闻发布会 □路演活动 现场参观 □其他 中信建投、中金公司、海通证券、国盛证券、泰康资产、浦银安盛、 参与单位名称（排 慎知资产、银华基金、长信基金、博裕资本、中加基金、华创证券、 名不分先后） 华鑫证券 时间 2023 年 6 月 6 日 9:00-12:00、2023 年 6 月 7 日 9:00-12:00 地点 兰考第一医院（河南兰考）、兖矿新里程总医院（山东邹城） 上市公司接待人员 姓名 董事会秘书、财务总监刘军 兰考第一医院（集团）： 1. 基本情况介绍： 兰考县是河南省直管县，县域面积 1116 平方公里，下辖 3 个街道办事处， 13 个乡镇，人口 87 万； 投资者关系活动主 兰考第一医院（集团）占地面积 140 余亩，建筑面积 12 万平方米，总资 要内容介绍 产 5.2 亿元，实际开放床位 1560 张，年门急诊量 120 万人次，年出院人次 7.5 万，年手术量 2.4 万台，下设机构有兰考第 ...

新里程健康科技集团股份有限公 2023 年第一季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 证券代码：002219 证券简称：新里程 公告编号：2023-044 新里程健康科技集团股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 新里程健康科技集团股份有限公 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 778,180,614.02 | 761,048,026.55 | 2.25% | | 归属于上 ...

投资者关系活动记录表 编号：2023-02 | | □分析师会议 特定对象调研 | | --- | --- | | 投资者关系活动 | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称（排 | Boyu Capital Investment Group、CPI Capital、HSBC、MassAve Global | | 名不分先后） | 大道寰球、Perseverance Asset Management L.L.P、Point72 Group、 | | | Sage Partners、Superstring Capital Management LP、Tiger Pacific | | | Capital LP、WT China Group、北京富国大通资管、北京汉和汉华 | | | 资本、博远基金、淡水泉投资、东北证券、东方红、东吴证券、冬 | | | 加基金、富国基金、高毅资产、工银安盛、工银瑞信基金、光大永 | | | 明、广发基金、广发证券、国金基金、国金证券、国联证券、国融 | | | 证券、国盛证券、国 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a year-over-year growth of 15%[4]. - The total revenue for 2022 was ¥3,152,734,880.63, representing a 4.53% increase from ¥3,016,070,733.20 in 2021[141]. - The net profit attributable to shareholders for 2022 was ¥155,621,958.97, a significant recovery from a loss of ¥371,431,516.93 in 2021, marking a 141.90% increase[141]. - The net cash flow from operating activities for 2022 was ¥91,209,535.37, compared to a loss of ¥415,431,630.35 in 2021, indicating a 121.96% improvement[141]. - Basic earnings per share for 2022 were ¥0.0477, a turnaround from a loss of ¥0.1991 in 2021, reflecting a 123.96% increase[141]. - The weighted average return on equity for 2022 was 9.52%, a significant recovery from -381.53% in 2021[141]. - The company reported a non-operating income of 64,412,423.60 yuan in 2022, compared to 44,000,113.42 yuan in 2021, indicating a significant increase[161]. - The company received government subsidies amounting to 17,827,702.87 yuan in 2022, up from 16,865,398.63 yuan in 2021, reflecting continued support for its operations[161]. - The company recorded a gain from debt restructuring of 47,318,475.58 yuan in 2022, compared to 24,336,243.21 yuan in 2021, highlighting improved financial management[161]. User Growth and Market Expansion - User data showed a growth in active users, reaching 5 million by the end of 2022, which is a 20% increase compared to the previous year[4]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB, driven by new product launches and market expansion strategies[4]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming to increase its customer base by 30%[4]. - A strategic acquisition was completed in Q3 2022, enhancing the company's service capabilities and expected to contribute an additional 200 million RMB in revenue annually[4]. Operational Efficiency and Cost Management - The company has committed to reducing operational costs by 15% over the next two years through efficiency improvements and technology integration[4]. - The gross profit margin improved to 40% in 2022, up from 35% in 2021, reflecting better cost management and pricing strategies[4]. - The company is exploring partnerships with local healthcare providers to enhance service delivery and customer engagement, targeting a 25% increase in service utilization[4]. - A new technology platform was launched in late 2022, aimed at improving user experience and expected to drive a 15% increase in user retention rates[4]. Legal and Financial Transactions - The company is involved in a lawsuit regarding a loan contract dispute, with the amount in question being 60 million yuan[19]. - The court has upheld the original ruling, rejecting the company's appeal[20]. - The company has not engaged in any related party transactions involving asset or equity acquisitions or sales during the reporting period[21]. - There are no deposit, loan, credit, or other financial transactions between the company's financial subsidiary and related parties[23]. - The company has provided guarantees totaling 30 million yuan for Wafangdian Third Hospital, which is not yet fulfilled[42]. - The company has also provided guarantees of 4.8 million yuan for Dalian Liaoyu Hospital, which has been fulfilled[42]. - A guarantee of 10 million yuan was provided for Kangxian Duyimai Biological Pharmaceutical Co., which has been fulfilled[42]. - The company has a guarantee of 1.6 million yuan for Pingxiang Ganzi Hospital, which is not yet fulfilled[42]. - The company has not disclosed any entrusted loans during the reporting period[29]. - The company has not made any significant changes to its share capital or shareholder structure during the reporting period[35]. - The company approved a total guarantee amount of 97,600,000 for subsidiaries during the reporting period, with an actual guarantee amount of 59,905,000[43]. - As of the end of the reporting period, the approved guarantee amount for subsidiaries was 127,600,000, with an actual guarantee balance of 51,721,260[43]. - The total actual guarantee amount accounted for 30.02% of the company's net assets[43]. - The company has entrusted 10,100,000 in bank financial products, with no overdue amounts or impairment provisions[44]. - The company has not provided guarantees for shareholders or related parties[43]. - The company has not reported any overdue amounts in its entrusted loans[45]. Shareholder and Capital Structure - The company changed its name from "Hengkang Medical Group Co., Ltd." to "New Journey Health Technology Group Co., Ltd." effective September 26, 2022[45]. - The total share capital increased from 1,865,236,430 shares to 3,264,163,753 shares following a capital reserve conversion plan, with a ratio of 10 shares to 7.5 shares[49]. - The company completed the capital reserve conversion registration on June 22, 2022[49]. - New Mile Health acquired 825,927,323 shares of Hengkang Medical, representing 25.30% of the total share capital after the capital increase[54]. - The total share capital of Hengkang Medical increased from approximately 1,865,236,430 shares to about 3,264,163,753 shares following a capital reserve conversion[53]. - The restructuring plan for Hengkang Medical was approved by the court on April 22, 2022[54]. - New Mile Health is now the controlling shareholder of Hengkang Medical, which has transitioned to a state without a practical controller[54]. - The number of ordinary shareholders increased from 34,517 to 39,935 during the reporting period[55]. - New Mile Health committed to not transferring its shares for 36 months post-acquisition to ensure stable development of Hengkang Medical[63]. - The company reported a significant increase in shareholding concentration with the top shareholder holding over 25%[55]. Goodwill and Impairment - As of December 31, 2022, the goodwill balance of the company was CNY 1,754.51 million, with an impairment provision of CNY 870.41 million, resulting in a net book value of CNY 884.10 million[94]. - The company conducts annual impairment tests on goodwill, which are based on the recoverable amount of asset groups that include goodwill, determined by the higher of the present value of expected future cash flows and the fair value of assets less disposal costs[94]. - The company reported that the key assumptions used in the impairment testing of goodwill are subject to inherent uncertainty and may be influenced by management bias[94]. - The company’s management evaluates the expected credit loss for accounts receivable based on the credit risk characteristics of each receivable[95]. - The total accounts receivable and other receivables amounted to CNY 1,988.91 million, with a bad debt provision of CNY 1,095.97 million, leading to a net value of CNY 892.94 million[95]. - The company reported that the net profit before and after deducting non-recurring gains and losses for the last three accounting years was negative, indicating ongoing uncertainty regarding its ability to continue as a going concern[141]. Strategic Initiatives and Healthcare Focus - The company has shifted its core business model from a single pharmaceutical manufacturing focus to a "big health" industry driven by both medical services and pharmaceutical manufacturing[106]. - The company has implemented a "1+N" development model in the medical sector, which includes a general hospital and multiple specialized hospitals[106]. - The company operates under a "1+N" model, focusing on major diseases related to aging, such as tumors and cardiovascular diseases, to enhance competitiveness and influence in the region[194]. - The company is actively expanding its hospital network, with new tumor hospital licenses approved for Wafangdian Third Hospital and Xuyi Traditional Chinese Medicine Hospital, and ongoing construction of a tumor center at Lankao First Hospital[194]. - The pharmaceutical manufacturing segment aims to create a competitive product matrix and influential consumer industry layout, leveraging the unique properties of its products to enter the fast-moving consumer goods market[197]. - The company emphasizes a "large specialty, strong comprehensive" approach, enhancing hospital rankings and clinical specialty levels, with several departments recognized as key specialties at the municipal and provincial levels[198]. - The company has been recognized for its excellence, with Wafangdian Hospital and Xuyi Traditional Chinese Medicine Hospital listed among the top hospitals in their respective categories[198]. - The ongoing healthcare reforms and increasing demand for quality medical services present significant growth opportunities for the company in the healthcare sector[197]. - The company aims to enhance regional medical center construction to address the imbalance in healthcare resources, particularly in the context of an aging population[168]. - The company emphasizes the importance of balancing economic and social benefits in its development strategy, particularly in the healthcare sector[168]. - The company has committed to promoting the integration of medical and elderly care services, aligning with national strategies to address population aging[167]. Market Trends and Demographics - The aging population in China is projected to reach 414 million by 2035, driving continuous growth in medical service demand[183]. - The total number of medical institutions in China reached 1,030,935 by the end of 2021, with hospitals increasing by 1,176, indicating a growing healthcare infrastructure[166]. - The total number of medical consultations in national healthcare institutions reached 8.47 billion, an increase of 730 million consultations (9.4% growth) compared to the previous year[193]. - The number of inpatient visits in national healthcare institutions was 24.726 million, an increase of 1.713 million visits (7.4% growth) year-on-year, with a resident annual hospitalization rate of 17.5%[193].